NCT06363981 Multisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression
| NCT ID | NCT06363981 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jakub Antczak |
| Condition | Unipolar Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-05-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-05-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression.
Eligibility Criteria
Inclusion Criteria: * severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion * Hamilton Depression Rating Scale between between 20 and 35 points at inclusion * The score in the Athens Insomnia Scale eight or more * The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2 * Complaining about problems with memory and concentration timely related with the onset of depression Exclusion Criteria: * Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * Psychotic symptoms at the time of inclusion * Suicidal ideations and/or attempts within three months prior to inclusion
Contact & Investigator
Wojciech Korzeniowski, MD
PRINCIPAL INVESTIGATOR
The Education of Research and Development Center, Babinski Clinical Hospital
Frequently Asked Questions
Who can join the NCT06363981 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Unipolar Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06363981 currently recruiting?
Yes, NCT06363981 is actively recruiting participants. Contact the research team at wojciech.korzen@gmail.com for enrollment information.
Where is the NCT06363981 trial being conducted?
This trial is being conducted at Krakow, Poland.
Who is sponsoring the NCT06363981 clinical trial?
NCT06363981 is sponsored by Jakub Antczak. The principal investigator is Wojciech Korzeniowski, MD at The Education of Research and Development Center, Babinski Clinical Hospital. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.